These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 10220753

  • 1. [The treatment of Parkinson disease].
    Jiménez-Jiménez FJ.
    Med Clin (Barc); 1999 Feb 27; 112(7):257-8. PubMed ID: 10220753
    [No Abstract] [Full Text] [Related]

  • 2. Iatrogenesis imperfecta.
    Friedman JH.
    Med Health R I; 2002 Jul 27; 85(7):198. PubMed ID: 12182087
    [No Abstract] [Full Text] [Related]

  • 3. [Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease].
    Alegre M, Noé E, Martínez Lage JM.
    Neurologia; 1997 Nov 27; 12(9):429. PubMed ID: 9471184
    [No Abstract] [Full Text] [Related]

  • 4. [Depressive syndrome, psychoses, dementia: frequent manifestations in Parkinson disease].
    Wedekind S.
    MMW Fortschr Med; 2005 Jun 02; 147(22):11. PubMed ID: 15977623
    [No Abstract] [Full Text] [Related]

  • 5. Pramipexole-induced psychosis in Parkinson's disease.
    Li CT, Tsai SJ, Hwang JP.
    Psychiatry Clin Neurosci; 2008 Apr 02; 62(2):245. PubMed ID: 18412854
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of pharmacotoxic psychoses with clopenthixol in patients with Parkinson's disease (author's transl)].
    Danielczyk W.
    Wien Klin Wochenschr; 1981 Aug 07; 93(15):500-1. PubMed ID: 7303692
    [Abstract] [Full Text] [Related]

  • 8. Mental disorders in Parkinson's disease.
    Rafal R.
    R I Med J (1976); 1986 Jul 07; 69(7):323-6. PubMed ID: 3462889
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002 Jul 07; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of later phases of Parkinson disease].
    Tison F.
    Rev Neurol (Paris); 2008 Apr 07; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract] [Full Text] [Related]

  • 12. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
    Papapetropoulos S.
    Clin Neuropharmacol; 2006 Apr 07; 29(1):59. PubMed ID: 16518136
    [No Abstract] [Full Text] [Related]

  • 13. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul 07; 73(7):733. PubMed ID: 12137117
    [No Abstract] [Full Text] [Related]

  • 14. [Hallucinations in Parkinson's disease].
    Moser A, Hagenah J, Kömpf D.
    Nervenarzt; 2003 Apr 07; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [Abstract] [Full Text] [Related]

  • 15. [Complications of drug withdrawal from antiparkinson agents and neuroleptics].
    Mizon JP, Rosa A.
    Therapie; 1984 Apr 07; 39(4):421-5. PubMed ID: 6148792
    [No Abstract] [Full Text] [Related]

  • 16. Recent advances in Parkinson's disease.
    Vécsei L.
    Ideggyogy Sz; 2002 Nov 20; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract] [Full Text] [Related]

  • 17. [Treatments in the early stage of Parkinson disease].
    Rascol O.
    Rev Neurol (Paris); 2008 Apr 20; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.
    Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM.
    Clin Neuropharmacol; 2006 Apr 20; 29(4):215-9. PubMed ID: 16855423
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.